Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Кардиоренальные эффекты финеренона и его место в терапии хронической болезни почек у пациентов с сахарным диабетом 2-го типа
Кардиоренальные эффекты финеренона и его место в терапии хронической болезни почек у пациентов с сахарным диабетом 2-го типа
Салухов В.В., Шамхалова М.Ш., Дуганова А.В. Кардиоренальные эффекты финеренона и его место в терапии хронической болезни почек у пациентов с сахарным диабетом 2-го типа. Терапевтический архив. 2023;95(3):261–273. DOI: 10.26442/00403660.2023.03.202152
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Хроническая болезнь почек (ХБП) – одно из самых частых осложнений сахарного диабета (СД) и независимый фактор риска сердечно-сосудистых заболеваний. Несмотря на терапию ХБП у пациентов с СД 2-го типа (СД 2) в соответствии с действующими рекомендациями, риск развития у них почечной недостаточности и сердечно-сосудистых осложнений остается высоким. До настоящего времени средства лечения ХБП у пациентов с СД 2 не устраняли остаточный риск прогрессирования поражения почек, связанный с воспалением и фиброзом. В обзоре представлены результаты исследований FIDELIO-DKD, FIGARO-DKD и их объединенного анализа FIDELITY, посвященных оценке эффективности и безопасности селективного нестероидного антагониста минералокортикоидных рецепторов финеренона в лечении больных СД 2 с ХБП различных стадий. Рассмотрены современные патофизиологические аспекты гиперактивации минералокортикоидных рецепторов и особенности их блокады стероидными и нестероидными антагонистами минералокортикоидных рецепторов, различия их фармакологических эффектов, преимущества и нежелательные явления финеренона в рандомизированных исследованиях. Приведены вероятные механизмы ранних и отсроченных эффектов финеренона, которые реализовались в благотворном влиянии на сердечно-сосудистые и почечные исходы у больных СД 2 с ХБП. Предложен практический протокол инициации и титрации финеренона, нацеленный на уменьшение риска гиперкалиемии. Проанализированы современные рекомендации, касающиеся терапии ХБП у больных СД 2, определено место финеренона в нефропротективной комбинированной терапии.
Ключевые слова: сахарный диабет 2-го типа, хроническая болезнь почек, диабетическая болезнь почек, сердечно-сосудистый риск, воспаление, фиброз, антагонисты минералокортикоидных рецепторов, финеренон, спиронолактон, эплеренон
Keywords: type 2 diabetes mellitus, chronic kidney disease, diabetic kidney disease, cardiovascular risk, inflammation, fibrosis, mineralocorticoid receptor antagonists, finerenone, spironolactone, eplerenone
Ключевые слова: сахарный диабет 2-го типа, хроническая болезнь почек, диабетическая болезнь почек, сердечно-сосудистый риск, воспаление, фиброз, антагонисты минералокортикоидных рецепторов, финеренон, спиронолактон, эплеренон
________________________________________________
Keywords: type 2 diabetes mellitus, chronic kidney disease, diabetic kidney disease, cardiovascular risk, inflammation, fibrosis, mineralocorticoid receptor antagonists, finerenone, spironolactone, eplerenone
Полный текст
Список литературы
1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-127. DOI:10.1016/j.kint.2022.06.008
2. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73. DOI:10.1016/S0140-6736(12)61350-6
3. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82 [Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82 (in Russian)].
4. Shenoy SV, Nagaraju SP, Bhojaraja MV, et al. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Nephrology (Carlton). 2021;26(11):858-71. DOI:10.1111/nep.13917
5. Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Попов С.И. Ингибиторы SGLT2 и почки: механизмы и основные эффекты у больных сахарным диабетом 2 типа. Сахарный диабет. 2020;23(5):475-91 [Salukhov VV, Khalimov YuSh, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes mellitus. 2020;23(5):475-91 (in Russian)]. DOI:10.14341/DM12123
6. Шамхалова М.Ш., Скляник И.А., Шестакова М.В. Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1. Сахарный диабет. 2020;23(1):56-64 [Shamkhalova MSh, Sklyanik IA, Shestakova MV. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Diabetes mellitus. 2020;23(1):56-64 (in Russian)]. DOI:10.14341/DM12286
7. Салухов В.B., Ковалевская Е.А. Переосмысление роли пиоглитазона в современной диабетологии с позиции его кардиоренопротективных свойств. Медицинский совет. 2022;10:10-21 [Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy sovet=Medical Council. 2022;10:10-21 (in Russian)]. DOI:10.21518/2079-701X-2022-16-10-10-21
8. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004. DOI:10.1002/14651858.CD007004.pub3
9. Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):181-91. DOI:10.1053/j.ackd.2017.12.002
10. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol. 2021;52(3):209-16. DOI:10.1159/000515622
11. Трубицына Н.П., Зайцева Н.В., Северина А.С., Шамхалова М.Ш. Хроническая болезнь почек у пациентов с сахарным диабетом 2 типа: новые мишени лекарственного воздействия. Сахарный диабет. 2022;25(5):492-8 [Trubitsyna NP, Zaitseva NV, Severina AS, Shamkhalova MS. Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action. Diabetes mellitus. 2022;25(5):492-8 (in Russian)]. DOI:10.14341/DM12944
12. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):1051-60. DOI:10.1038/ki.2011.48
13. Lytvyn Y, Godoy LC, Scholtes RA, et al. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep. 2019;19(1):4. DOI:10.1007/s11892-019-1123-8
14. Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders – New perspectives for combination therapy. Pharmacol Res. 2021;172:105859. DOI:10.1016/j.phrs.2021.105859
15. Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol. 2022;84:585-610.
DOI:10.1146/annurev-physiol-060821-013950
16. Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Exp Rev Clin Pharmacol. 2022;15(5):501-13. DOI:10.1080/17512433.2022.2094770
17. Le Billan F, Perrot J, Carceller E, et al. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J. 2021;35(2):e21314. DOI:10.1096/fj.202002043RR
18. Abedini A, Wu J, Ma Z, et al. Revealing the antifibrotic mechanism of finerenone in the DOCA-salt nephropathy rat model using single nuclei and bulk transcriptomics. J Am Soc Nephrol. 2021;32:765
19. González-Blázquez R, Somoza B, Gil-Ortega M, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. DOI:10.3389/fphar.2018.01131
20. Alexandrou ME, Theodorakopoulou MP, Sarafidis PA. Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Kidney Dial. 2022;2(2):163-82. DOI:10.3390/kidneydial2020019
21. Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018;71(4):599-608. DOI:10.1161/HYPERTENSIONAHA.117.10360
22. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29. DOI:10.1056/NEJMoa2025845
23. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-44. DOI:10.1159/000503713
24. Filippatos G, Bakris GL, Pitt B, et al; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021;78(2):142-52. DOI:10.1016/j.jacc.2021.04.079
25. Leon SJ, Tangri N. Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges. Kidney360. 2022;3(8):1442-4. DOI:10.34067/KID.0000952022
26. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-63. DOI:10.1056/NEJMoa2110956
27. Ruilope LM, Agarwal R, Anker SD, et al; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):345-56. DOI:10.1159/000503712
28. Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38(2):372-83. DOI:10.1093/ndt/gfac157
29. Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022;23(16):9243. DOI:10.3390/ijms23169243
30. Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. DOI:10.1093/eurheartj/ehab777
31. Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci (Lond). 2022;136(12):1005-17. DOI:10.1042/CS20220212
32. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14. DOI:10.1093/eurheartj/ehw132
33. Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295-302. DOI:10.1097/hjh.0000000000003330
34. Ruilope LM, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022;79(12):2685-95. DOI:10.1161/HYPERTENSIONAHA.122.19744
35. Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494-510 [Salukhov VV, Demidova TY. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. Diabetes mellitus. 2016;19(6):494-510 (in Russian)]. DOI:10.14341/DM8216
36. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63. DOI:10.1093/eurheartj/eht187
37. Filippatos G, Anker SD, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-52. DOI:10.1161/CIRCULATIONAHA.120.051898
38. Filippatos G, Bakris G, Agarwal A, et al. FIDELITY: Effect of finerenone by LVH subgroup. LBT Pharmacological treatment II, Heart Failure 2022, 21–24 May, Madrid, Spain. Available at: https://conferences.medicom-publishers.com/specialisation/cardiology/hfa-2022/fidelity-cardiorenal-b... Accessed: 09.06.2022.
39. ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S191-202. DOI:10.2337/dc23-S011
40. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923-1049. DOI:10.1016/j.eprac.2022.08.002
41. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-66. DOI:10.1007/s00125-022-05787-2
42. Agarwal R, Joseph A, Anker SD, et al; FIDELIO-DKD Investigators. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225-37. DOI:10.1681/ASN.2021070942
43. Shaikh A, Ray J, Campbell KN. Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Ther Clin Risk Manag. 2022;18:753-60. DOI:10.2147/TCRM.S325916
44. Wanner C, Fioretto P, Kovesdy CP, et al. Potassium management with finerenone: Practical aspects. Endocrinol Diabetes Metab. 2022;5(6):e360. DOI:10.1002/edm2.360
45. Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-52. DOI:10.1159/000516213
46. Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. 2018;314(5):F969-84. DOI:10.1152/ajprenal.00551.2017
47. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-61. DOI:10.1093/eurheartj/ehaa736
2. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73. DOI:10.1016/S0140-6736(12)61350-6
3. Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82 (in Russian).
4. Shenoy SV, Nagaraju SP, Bhojaraja MV, et al. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Nephrology (Carlton). 2021;26(11):858-71. DOI:10.1111/nep.13917
5. Salukhov VV, Khalimov YuSh, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes mellitus. 2020;23(5):475-91 (in Russian). DOI:10.14341/DM12123
6. Shamkhalova MSh, Sklyanik IA, Shestakova MV. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Diabetes mellitus. 2020;23(1):56-64 (in Russian). DOI:10.14341/DM12286
7. Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy sovet=Medical Council. 2022;10:10-21 (in Russian). DOI:10.21518/2079-701X-2022-16-10-10-21
8. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004. DOI:10.1002/14651858.CD007004.pub3
9. Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):181-91. DOI:10.1053/j.ackd.2017.12.002
10. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol. 2021;52(3):209-16. DOI:10.1159/000515622
11. Trubitsyna NP, Zaitseva NV, Severina AS, Shamkhalova MS. Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action. Diabetes mellitus. 2022;25(5):492-8 (in Russian). DOI:10.14341/DM12944
12. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):1051-60. DOI:10.1038/ki.2011.48
13. Lytvyn Y, Godoy LC, Scholtes RA, et al. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep. 2019;19(1):4. DOI:10.1007/s11892-019-1123-8
14. Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders – New perspectives for combination therapy. Pharmacol Res. 2021;172:105859. DOI:10.1016/j.phrs.2021.105859
15. Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol. 2022;84:585-610.
DOI:10.1146/annurev-physiol-060821-013950
16. Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Exp Rev Clin Pharmacol. 2022;15(5):501-13. DOI:10.1080/17512433.2022.2094770
17. Le Billan F, Perrot J, Carceller E, et al. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J. 2021;35(2):e21314. DOI:10.1096/fj.202002043RR
18. Abedini A, Wu J, Ma Z, et al. Revealing the antifibrotic mechanism of finerenone in the DOCA-salt nephropathy rat model using single nuclei and bulk transcriptomics. J Am Soc Nephrol. 2021;32:765
19. González-Blázquez R, Somoza B, Gil-Ortega M, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. DOI:10.3389/fphar.2018.01131
20. Alexandrou ME, Theodorakopoulou MP, Sarafidis PA. Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Kidney Dial. 2022;2(2):163-82. DOI:10.3390/kidneydial2020019
21. Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018;71(4):599-608. DOI:10.1161/HYPERTENSIONAHA.117.10360
22. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29. DOI:10.1056/NEJMoa2025845
23. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-44. DOI:10.1159/000503713
24. Filippatos G, Bakris GL, Pitt B, et al; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021;78(2):142-52. DOI:10.1016/j.jacc.2021.04.079
25. Leon SJ, Tangri N. Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges. Kidney360. 2022;3(8):1442-4. DOI:10.34067/KID.0000952022
26. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-63. DOI:10.1056/NEJMoa2110956
27. Ruilope LM, Agarwal R, Anker SD, et al; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):345-56. DOI:10.1159/000503712
28. Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38(2):372-83. DOI:10.1093/ndt/gfac157
29. Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022;23(16):9243. DOI:10.3390/ijms23169243
30. Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. DOI:10.1093/eurheartj/ehab777
31. Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci (Lond). 2022;136(12):1005-17. DOI:10.1042/CS20220212
32. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14. DOI:10.1093/eurheartj/ehw132
33. Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295-302. DOI:10.1097/hjh.0000000000003330
34. Ruilope LM, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022;79(12):2685-95. DOI:10.1161/HYPERTENSIONAHA.122.19744
35. Salukhov VV, Demidova TY. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. Diabetes mellitus. 2016;19(6):494-510 (in Russian). DOI:10.14341/DM8216
36. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63. DOI:10.1093/eurheartj/eht187
37. Filippatos G, Anker SD, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-52. DOI:10.1161/CIRCULATIONAHA.120.051898
38. Filippatos G, Bakris G, Agarwal A, et al. FIDELITY: Effect of finerenone by LVH subgroup. LBT Pharmacological treatment II, Heart Failure 2022, 21–24 May, Madrid, Spain. Available at: https://conferences.medicom-publishers.com/specialisation/cardiology/hfa-2022/fidelity-cardiorenal-b... Accessed: 09.06.2022.
39. ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S191-202. DOI:10.2337/dc23-S011
40. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923-1049. DOI:10.1016/j.eprac.2022.08.002
41. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-66. DOI:10.1007/s00125-022-05787-2
42. Agarwal R, Joseph A, Anker SD, et al; FIDELIO-DKD Investigators. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225-37. DOI:10.1681/ASN.2021070942
43. Shaikh A, Ray J, Campbell KN. Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Ther Clin Risk Manag. 2022;18:753-60. DOI:10.2147/TCRM.S325916
44. Wanner C, Fioretto P, Kovesdy CP, et al. Potassium management with finerenone: Practical aspects. Endocrinol Diabetes Metab. 2022;5(6):e360. DOI:10.1002/edm2.360
45. Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-52. DOI:10.1159/000516213
46. Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. 2018;314(5):F969-84. DOI:10.1152/ajprenal.00551.2017
47. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-61. DOI:10.1093/eurheartj/ehaa736
2. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73. DOI:10.1016/S0140-6736(12)61350-6
3. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82 [Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82 (in Russian)].
4. Shenoy SV, Nagaraju SP, Bhojaraja MV, et al. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Nephrology (Carlton). 2021;26(11):858-71. DOI:10.1111/nep.13917
5. Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Попов С.И. Ингибиторы SGLT2 и почки: механизмы и основные эффекты у больных сахарным диабетом 2 типа. Сахарный диабет. 2020;23(5):475-91 [Salukhov VV, Khalimov YuSh, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes mellitus. 2020;23(5):475-91 (in Russian)]. DOI:10.14341/DM12123
6. Шамхалова М.Ш., Скляник И.А., Шестакова М.В. Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1. Сахарный диабет. 2020;23(1):56-64 [Shamkhalova MSh, Sklyanik IA, Shestakova MV. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Diabetes mellitus. 2020;23(1):56-64 (in Russian)]. DOI:10.14341/DM12286
7. Салухов В.B., Ковалевская Е.А. Переосмысление роли пиоглитазона в современной диабетологии с позиции его кардиоренопротективных свойств. Медицинский совет. 2022;10:10-21 [Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy sovet=Medical Council. 2022;10:10-21 (in Russian)]. DOI:10.21518/2079-701X-2022-16-10-10-21
8. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004. DOI:10.1002/14651858.CD007004.pub3
9. Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):181-91. DOI:10.1053/j.ackd.2017.12.002
10. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol. 2021;52(3):209-16. DOI:10.1159/000515622
11. Трубицына Н.П., Зайцева Н.В., Северина А.С., Шамхалова М.Ш. Хроническая болезнь почек у пациентов с сахарным диабетом 2 типа: новые мишени лекарственного воздействия. Сахарный диабет. 2022;25(5):492-8 [Trubitsyna NP, Zaitseva NV, Severina AS, Shamkhalova MS. Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action. Diabetes mellitus. 2022;25(5):492-8 (in Russian)]. DOI:10.14341/DM12944
12. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):1051-60. DOI:10.1038/ki.2011.48
13. Lytvyn Y, Godoy LC, Scholtes RA, et al. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep. 2019;19(1):4. DOI:10.1007/s11892-019-1123-8
14. Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders – New perspectives for combination therapy. Pharmacol Res. 2021;172:105859. DOI:10.1016/j.phrs.2021.105859
15. Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol. 2022;84:585-610.
DOI:10.1146/annurev-physiol-060821-013950
16. Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Exp Rev Clin Pharmacol. 2022;15(5):501-13. DOI:10.1080/17512433.2022.2094770
17. Le Billan F, Perrot J, Carceller E, et al. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J. 2021;35(2):e21314. DOI:10.1096/fj.202002043RR
18. Abedini A, Wu J, Ma Z, et al. Revealing the antifibrotic mechanism of finerenone in the DOCA-salt nephropathy rat model using single nuclei and bulk transcriptomics. J Am Soc Nephrol. 2021;32:765
19. González-Blázquez R, Somoza B, Gil-Ortega M, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. DOI:10.3389/fphar.2018.01131
20. Alexandrou ME, Theodorakopoulou MP, Sarafidis PA. Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Kidney Dial. 2022;2(2):163-82. DOI:10.3390/kidneydial2020019
21. Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018;71(4):599-608. DOI:10.1161/HYPERTENSIONAHA.117.10360
22. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29. DOI:10.1056/NEJMoa2025845
23. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-44. DOI:10.1159/000503713
24. Filippatos G, Bakris GL, Pitt B, et al; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021;78(2):142-52. DOI:10.1016/j.jacc.2021.04.079
25. Leon SJ, Tangri N. Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges. Kidney360. 2022;3(8):1442-4. DOI:10.34067/KID.0000952022
26. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-63. DOI:10.1056/NEJMoa2110956
27. Ruilope LM, Agarwal R, Anker SD, et al; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):345-56. DOI:10.1159/000503712
28. Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38(2):372-83. DOI:10.1093/ndt/gfac157
29. Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022;23(16):9243. DOI:10.3390/ijms23169243
30. Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. DOI:10.1093/eurheartj/ehab777
31. Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci (Lond). 2022;136(12):1005-17. DOI:10.1042/CS20220212
32. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14. DOI:10.1093/eurheartj/ehw132
33. Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295-302. DOI:10.1097/hjh.0000000000003330
34. Ruilope LM, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022;79(12):2685-95. DOI:10.1161/HYPERTENSIONAHA.122.19744
35. Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494-510 [Salukhov VV, Demidova TY. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. Diabetes mellitus. 2016;19(6):494-510 (in Russian)]. DOI:10.14341/DM8216
36. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63. DOI:10.1093/eurheartj/eht187
37. Filippatos G, Anker SD, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-52. DOI:10.1161/CIRCULATIONAHA.120.051898
38. Filippatos G, Bakris G, Agarwal A, et al. FIDELITY: Effect of finerenone by LVH subgroup. LBT Pharmacological treatment II, Heart Failure 2022, 21–24 May, Madrid, Spain. Available at: https://conferences.medicom-publishers.com/specialisation/cardiology/hfa-2022/fidelity-cardiorenal-b... Accessed: 09.06.2022.
39. ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S191-202. DOI:10.2337/dc23-S011
40. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923-1049. DOI:10.1016/j.eprac.2022.08.002
41. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-66. DOI:10.1007/s00125-022-05787-2
42. Agarwal R, Joseph A, Anker SD, et al; FIDELIO-DKD Investigators. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225-37. DOI:10.1681/ASN.2021070942
43. Shaikh A, Ray J, Campbell KN. Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Ther Clin Risk Manag. 2022;18:753-60. DOI:10.2147/TCRM.S325916
44. Wanner C, Fioretto P, Kovesdy CP, et al. Potassium management with finerenone: Practical aspects. Endocrinol Diabetes Metab. 2022;5(6):e360. DOI:10.1002/edm2.360
45. Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-52. DOI:10.1159/000516213
46. Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. 2018;314(5):F969-84. DOI:10.1152/ajprenal.00551.2017
47. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-61. DOI:10.1093/eurheartj/ehaa736
________________________________________________
2. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73. DOI:10.1016/S0140-6736(12)61350-6
3. Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82 (in Russian).
4. Shenoy SV, Nagaraju SP, Bhojaraja MV, et al. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Nephrology (Carlton). 2021;26(11):858-71. DOI:10.1111/nep.13917
5. Salukhov VV, Khalimov YuSh, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes mellitus. 2020;23(5):475-91 (in Russian). DOI:10.14341/DM12123
6. Shamkhalova MSh, Sklyanik IA, Shestakova MV. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Diabetes mellitus. 2020;23(1):56-64 (in Russian). DOI:10.14341/DM12286
7. Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy sovet=Medical Council. 2022;10:10-21 (in Russian). DOI:10.21518/2079-701X-2022-16-10-10-21
8. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004. DOI:10.1002/14651858.CD007004.pub3
9. Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):181-91. DOI:10.1053/j.ackd.2017.12.002
10. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol. 2021;52(3):209-16. DOI:10.1159/000515622
11. Trubitsyna NP, Zaitseva NV, Severina AS, Shamkhalova MS. Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action. Diabetes mellitus. 2022;25(5):492-8 (in Russian). DOI:10.14341/DM12944
12. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):1051-60. DOI:10.1038/ki.2011.48
13. Lytvyn Y, Godoy LC, Scholtes RA, et al. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep. 2019;19(1):4. DOI:10.1007/s11892-019-1123-8
14. Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders – New perspectives for combination therapy. Pharmacol Res. 2021;172:105859. DOI:10.1016/j.phrs.2021.105859
15. Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol. 2022;84:585-610.
DOI:10.1146/annurev-physiol-060821-013950
16. Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Exp Rev Clin Pharmacol. 2022;15(5):501-13. DOI:10.1080/17512433.2022.2094770
17. Le Billan F, Perrot J, Carceller E, et al. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J. 2021;35(2):e21314. DOI:10.1096/fj.202002043RR
18. Abedini A, Wu J, Ma Z, et al. Revealing the antifibrotic mechanism of finerenone in the DOCA-salt nephropathy rat model using single nuclei and bulk transcriptomics. J Am Soc Nephrol. 2021;32:765
19. González-Blázquez R, Somoza B, Gil-Ortega M, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. DOI:10.3389/fphar.2018.01131
20. Alexandrou ME, Theodorakopoulou MP, Sarafidis PA. Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Kidney Dial. 2022;2(2):163-82. DOI:10.3390/kidneydial2020019
21. Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018;71(4):599-608. DOI:10.1161/HYPERTENSIONAHA.117.10360
22. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29. DOI:10.1056/NEJMoa2025845
23. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-44. DOI:10.1159/000503713
24. Filippatos G, Bakris GL, Pitt B, et al; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021;78(2):142-52. DOI:10.1016/j.jacc.2021.04.079
25. Leon SJ, Tangri N. Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges. Kidney360. 2022;3(8):1442-4. DOI:10.34067/KID.0000952022
26. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-63. DOI:10.1056/NEJMoa2110956
27. Ruilope LM, Agarwal R, Anker SD, et al; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):345-56. DOI:10.1159/000503712
28. Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38(2):372-83. DOI:10.1093/ndt/gfac157
29. Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022;23(16):9243. DOI:10.3390/ijms23169243
30. Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. DOI:10.1093/eurheartj/ehab777
31. Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci (Lond). 2022;136(12):1005-17. DOI:10.1042/CS20220212
32. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14. DOI:10.1093/eurheartj/ehw132
33. Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2):295-302. DOI:10.1097/hjh.0000000000003330
34. Ruilope LM, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022;79(12):2685-95. DOI:10.1161/HYPERTENSIONAHA.122.19744
35. Salukhov VV, Demidova TY. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus. Diabetes mellitus. 2016;19(6):494-510 (in Russian). DOI:10.14341/DM8216
36. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63. DOI:10.1093/eurheartj/eht187
37. Filippatos G, Anker SD, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-52. DOI:10.1161/CIRCULATIONAHA.120.051898
38. Filippatos G, Bakris G, Agarwal A, et al. FIDELITY: Effect of finerenone by LVH subgroup. LBT Pharmacological treatment II, Heart Failure 2022, 21–24 May, Madrid, Spain. Available at: https://conferences.medicom-publishers.com/specialisation/cardiology/hfa-2022/fidelity-cardiorenal-b... Accessed: 09.06.2022.
39. ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S191-202. DOI:10.2337/dc23-S011
40. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923-1049. DOI:10.1016/j.eprac.2022.08.002
41. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-66. DOI:10.1007/s00125-022-05787-2
42. Agarwal R, Joseph A, Anker SD, et al; FIDELIO-DKD Investigators. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225-37. DOI:10.1681/ASN.2021070942
43. Shaikh A, Ray J, Campbell KN. Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Ther Clin Risk Manag. 2022;18:753-60. DOI:10.2147/TCRM.S325916
44. Wanner C, Fioretto P, Kovesdy CP, et al. Potassium management with finerenone: Practical aspects. Endocrinol Diabetes Metab. 2022;5(6):e360. DOI:10.1002/edm2.360
45. Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-52. DOI:10.1159/000516213
46. Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol. 2018;314(5):F969-84. DOI:10.1152/ajprenal.00551.2017
47. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-61. DOI:10.1093/eurheartj/ehaa736
Авторы
В.В. Салухов*1, М.Ш. Шамхалова2, А.В. Дуганова1
1 ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*vlasaluk@yandex.ru
1 Kirov Military Medical Academy, Saint Petersburg, Russia;
2 Endocrinology Research Centre, Moscow, Russia
*vlasaluk@yandex.ru
1 ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*vlasaluk@yandex.ru
________________________________________________
1 Kirov Military Medical Academy, Saint Petersburg, Russia;
2 Endocrinology Research Centre, Moscow, Russia
*vlasaluk@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.